The abstracts summarize initial study data from using the CLS TRANBERG® Thermal Therapy System, with US-fusion image-guidance and treatment control using temperature probes, in the ongoing studies.
Both abstracts provide the latest insights into the clinical use of focal laser ablation for prostate cancer, contributing to the ongoing development of minimally invasive cancer therapies. The abstracts are now publicly available and can be accessed here.
Dr Blascke et al conclude that “FLA for prostate cancer appears to be feasible and safe, providing promising oncological control in localized prostate cancer. The procedure was well-tolerated and could be a valuable addition to focal therapy options for prostate cancer.”
The conclusion by Dr Henry and Dr Bailly was that “FLA appears effective for treating anterior and lateral prostate areas in localized cancer (ISUP 1 or 2), with minimal side effects. The technique is faster and more cost-effective than MRI-guided methods, offering comparable outcomes with real-time temperature control and reliable safety margins.”
Ultrasound-guided Focal Laser Ablation in Patients with Localized Prostate Cancer: Oncological Outcome after 6 Months Follow-Up in the Pro-FLA Trial, by Simon Blaschke, Alexander Fehr, Melis Gür, Christian Samtleben, Frank Fischbach, and Martin Schostak. See the poster here.
Poster #FTS4-1:
First French Cases of Localized Prostate Cancer Treatment by Focal Laser Ablation (FLA) Using TRANBERG® Thermal Therapy System, by Pierre Charles Henry and Dr. Vincent Bailly. See the poster here.
CLS extends our heartfelt congratulations to Dr. Henry, Dr. Blaschke, and their collaborators, for their contributions to advancing the field of focal therapy and prostate cancer treatment.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
